Chemoradiation followed by surgery for patients with cT4 oesophageal cancer - TOR-study (T4 Oesophagus Resection)

Academisch Medisch Centrum0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•Histologically proven squamous cell carcinoma, adenocarcinoma or undifferentiated carcinoma of the intrathoracic esophagus or gastro esophageal junction
•Surgical irresectable (T4a and T4b), as determined by Endoscopic Ultra Sound (EUS), CT scan of neck, thorax and abdomen OR Positon Emission Tomography (PET)-scan, without distant metastasis (T4a: ingrowth in pleura, pericardium, diaphragm, or adjacent peritoneum, T4b other adjacent structures,e.g. aorta, vertebral body, trachea)

•cT4b oesophageal carcinoma with tracheobronchial involvement, as demonstrated on bronchoscopy after neoadjuvant treatment
•Past or current history of malignancy other than entry diagnosis except for non-melanomatous skin cancer, or curatively treated in situ carcinoma of the cervix, or malignancy more than 5 years prior to enrollment
•Pregnancy (positive serum pregnancy test) and lactation
•Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) <= 1 year before enrollment
•Active infection or other serious underlying medical condition which would impair the ability of the patient to receive the planned treatment
•Dementia or altered mental status that would prohibit the understanding and giving of informed consent
•Inadequate caloric- and/or fluid intake
•Weight loss > 15%.

发起方